At a glance
- Originator Immungenetics
- Class Antidementias; Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-II for Alzheimer's disease in Germany (PO) (Immungenetics pipeline, February 2022)
- 01 Dec 2021 Immungenetics completes the phase II drainAD trial in Alzheimer's disease in Germany (unspecified route) (NCT03417986)
- 26 Mar 2018 Chemical structure information added